iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

[ad_1] BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by…